Answers are grounded in this paper and cite their sources.
The Inflation Reduction Act gave Medicare new authority to negotiate the prices it pays for certain high-cost prescription drugs. As the program enters its third cycle, a central question remains: how should Medicare determine a fair price? CMS has thus far provided limited detail on how evidence about a drug’s benefits, risks, and value shapes the final negotiated price, making the process difficult for patients, manufacturers, and other stakeholders to understand or anticipate. Over three negotiation cycles, the Institute for Clinical and Economic Review (ICER) has submitted independent analyses to CMS to inform these decisions. This work has required new approaches to estimating reasonable price benchmarks, incorporating real-world evidence on clinical benefits and long-term safety, and assessing drugs used to treat multiple conditions. Drawing on this experience, we identify lessons for improving Medicare drug price negotiation and recommend greater stakeholder engagement and clearer explanations of how evidence informs negotiated prices.
No takes yet. Share an insight, caveat, or question.
Richardson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: